Gritstone bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Updates
March 09, 2023 16:05 ET
|
Gritstone bio
-- Preliminary data from GRANITE Phase 2/3 study (individualized vaccine for first-line microsatellite-stable colorectal cancer [MSS-CRC]) remain expected in 4Q 2023 -- -- Phase 1/2 efficacy signals...
Gritstone bio to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update on March 9, 2023
March 02, 2023 07:00 ET
|
Gritstone bio
EMERYVILLE, Calif., March 02, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced...
Gritstone bio to Participate in 43rd Annual Cowen Healthcare Conference
February 27, 2023 16:06 ET
|
Gritstone bio
EMERYVILLE, Calif., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced...
Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 27, 2023 16:05 ET
|
Gritstone bio
EMERYVILLE, Calif., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today...
Gritstone bio and the National Cancer Institute (NCI) Establish a Clinical Trial Agreement to Evaluate a Neoantigen Cell Therapy-Vaccine Combination
February 14, 2023 07:00 ET
|
Gritstone bio
EMERYVILLE, Calif., Feb. 14, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced...
Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 24, 2023 07:00 ET
|
Gritstone bio
EMERYVILLE, Calif., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today...
Gritstone bio to Participate in Upcoming Investor Conferences
January 18, 2023 17:30 ET
|
Gritstone bio
EMERYVILLE, Calif., Jan. 18, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced...
Gritstone bio to Present at 41st Annual J.P. Morgan Healthcare Conference
December 15, 2022 16:31 ET
|
Gritstone bio
EMERYVILLE, Calif., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced...
Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 15, 2022 16:30 ET
|
Gritstone bio
EMERYVILLE, Calif., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today...
Gritstone bio Granted Two New U.S. Patents for Self-amplifying mRNA (samRNA)
December 13, 2022 07:00 ET
|
Gritstone bio
EMERYVILLE, Calif., Dec. 13, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced...